Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
Legend Biotech Corporation announced it will host an investor conference call to discuss its financial results for the third quarter of 2026.
Stocks · News reference
Legend Biotech Announces Multiple Abstracts Accepted for 2026 ASH Annual Meeting
Legend Biotech will present new clinical and real-world data for CARVYKTI and updates on its next-generation cell therapy programs at the 2026 American Society of Hematology (ASH) Annual Meeting.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Legend Biotech Says FDA Cleared In Vivo CAR-T Therapy LB2501 For U.S. Phase 1/2 Trial In B-Cell Cancers
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.
JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33
JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.